OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
COVID-19 therapies development, review processes geared to accelerate.
Overcoming capacity, supply chain, and technology hurdles.
Filling vaccine vials and syringes must be fast and GMP-compliant.
January 15, 2021
This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.
The CPhI event, which was originally scheduled for Aug. 31–Sept. 2, 2021 at the Fiera Milano in Milan, Italy, will be rescheduled for Nov. 9–11, 2021 at the same venue.
January 14, 2021
A report on the FDA PREPP initiative’s work in 2020 aims to strengthen the Agency’s response to future public health emergencies.
January 11, 2021
Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany facility to prepare Novavax’s COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.
The company plans to expand its global production capacity across six existing manufacturing facilities in Europe and the United States, as well as a new manufacturing facility in the US.
January 07, 2021
Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.
The company plans to deliver initial doses by mid-2021, and Australia will have the option to purchase up to 10 million additional doses through the agreement.
The European Commission has granted a conditional marketing authorization to Moderna for its COVID-19 vaccine.
January 06, 2021
Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, recognizes efforts of the pharmaceutical industry in combatting the COVID-19 pandemic.
January 05, 2021
Amid pressure to get more vaccines administered faster, FDA pushes back against changes in dosing regimens.